Ebola: WHO approves use of untested drugs, toll 1,013

Image
IANS
Last Updated : Aug 12 2014 | 7:00 PM IST

Geneva, Aug 12 (IANS/EFE) The toll from the Ebola virus disease in West Africa has risen to 1,013, leading the World Health Organisation (WHO) Tuesday to approve the use of experimental drugs to fight the disease.

The UN health institution indicated that 52 more patients had died since last Friday, while there were 69 new cases over the same period, bringing the number of affected to 1,848.

In a statement, the WHO's Ethics Committee said that in the light of the scale of the outbreak and the high number of deaths, it was ethical to use untested drugs against the Ebola virus.

The announcement came as Liberia, one of the worst-affected countries with 323 deaths and 599 cases, prepared to receive experimental treatment from the US in the coming days.

Washington Tuesday agreed to provide Liberia with experimental serum ZMapp, which has been used with success on two US aid workers infected with Ebola in Liberia and repatriated to the US.

The move came after Liberia's President, Ellen Johnson Sirleaf, asked the US for the drug to fight the virus.

The White House and the US Food and Drug Administration (FDA) approved the request for the serum to treat Liberian doctors currently infected with the Ebola virus.

A US government representative is expected to bring the drug into the country later this week.

Liberia registered the highest number of new infections and deaths between Aug 7 and 9, when 29 patients lost their lives and 45 new infections were recorded, the WHO reported Tuesday.

Sierra Leone followed with 17 deaths and 13 new patients, while six people died and 11 new cases were recorded in Guinea Conakry over that period.

Overall, Guinea is the country with the highest mortality, with 373 deaths, followed by Liberia with 323.

In Sierra Leone, the toll has risen to 315 out of 730 cases, and in Nigeria only 13 cases have been diagnosed, of which two were fatal.

--IANS/EFE

ab/dg

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 12 2014 | 6:54 PM IST

Next Story